GlassScriptPhysician profile
Gregory A George
NPI 1417909243
$6,705.45
in general payments reported to CMS, 2019-2025
31 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what 85% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $215 · 2021: $887 · 2022: $1,294 · 2023: $1,433 · 2024: $1,317 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,837 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,836.86 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,889.32 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $872.07 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $636.08 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $613.66 | 2021-2025 | |
| Novo Nordisk INC | $366.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.51 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $281.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $233.64 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $201.22 | 2019-2023 | Steglatro |
| Janssen Pharmaceuticals, INC | $163.41 | 2019-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $162.84 | 2023-2025 | Rexulti |
| Amgen INC. | $161.80 | 2021-2025 | Repatha, Otezla, Otezla |
| Boston Scientific Corporation | $143.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.58 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $122.76 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $97.67 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.12 | 2025 | Caplyta |
| Amarin Pharma, INC. | $40.05 | 2019-2022 | |
| Lundbeck LLC | $25.55 | 2023 | Rexulti |
| Edwards Lifesciences Corporation | $23.67 | 2022 | |
| Acadia Pharmaceuticals INC | $20.86 | 2022 | |
| Neurelis, INC. | $19.12 | 2023 | Valtoco |
| Dexcom, INC. | $18.26 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $16.52 | 2025 | Austedo Xr |
| Evoke Pharma, INC. | $14.93 | 2022 | |
| Abbott Laboratories | $14.71 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.16 | 2022 | |
| Genentech USA, INC. | $14.12 | 2021 | |
| Athena Bioscience, LLC | $13.53 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.42 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.